Altimmune (ALT) Stock: Analyst Consensus Points to $17 Target and +730% Upside Potential

Key Takeaways

• The central price target of $17 is the arithmetic mean of seven current, attributable analyst price targets reviewed for Altimmune, Inc. (ALT), a late clinical-stage biopharmaceutical company focused on liver and metabolic diseases.
• With the stock near $2.04, reaching $17 would require a rise of roughly 730% — an extremely large move that reflects the speculative, pre-revenue nature of the business.
• Individual analyst targets span a wide range from $10 (Leerink Partners) to $28 (Jefferies), highlighting deep disagreement about the value of lead drug candidate pemvidutide.
• The strongest supporting factor is pemvidutide, a GLP-1/glucagon dual receptor agonist in Phase 3 for MASH (metabolic dysfunction-associated steatohepatitis) with positive Phase 2 results in alcohol use disorder (AUD).
• The biggest risks are ongoing cash burn, clinical and regulatory execution risk, and intense competition from far larger, better-funded rivals in the obesity and liver-disease space.
• For more detail on ALT, explore the Major News, Today's Price Move, Forecast, and Earnings pages.
• For AI-driven idea generation and market monitoring, explore Trending AI Robots.

Analyst Price Targets and Consensus View

Altimmune, Inc. (ALT) is a pre-revenue biotech whose valuation rests almost entirely on the clinical and commercial potential of pemvidutide, its lead GLP-1/glucagon dual receptor agonist. Seven current, attributable price targets were reviewed, spanning roughly $10 to $28. The arithmetic mean of these targets is $17.00, which serves as the central target used throughout this article. For context, S&P Global's published average of about $17.11 across ten analysts is broadly consistent with this figure.

The range is exceptionally wide, which is typical of early-stage biotech where different analysts apply different probability-of-success assumptions. Recent revisions have generally trended lower as firms adjusted for share-count dilution and moderated revenue expectations: Evercore ISI lowered its target to $17 from $18 (September 2026), H.C. Wainwright to $20 from $25, and Citizens JMP to $11 from $14. Barclays and H.C. Wainwright each hold $20 targets, while Jefferies maintains the highest at $28. Notably, William Blair and Truist publish ratings but no price target, and at least one research shop carries a sell-equivalent view, underscoring that the analyst community is not unanimous. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

ALT last traded around $2.04, near the lower end of its 52-week range of roughly $2.02 to $6.44. Reaching $17 implies upside of approximately 730%, which must be characterized as a very large move by any standard. Such a move would require not merely favorable data but a fundamental repricing of the company's entire risk profile — something that in biotech typically occurs only through pivotal trial success, a partnership, or a takeover.

The path toward the target would depend heavily on pemvidutide's Phase 3 MASH program (the PERFORMA trial), whose 52-week topline readout is not expected until 2029, and on progress in AUD. Positive Phase 2 RECLAIM results in alcohol use disorder, reported in mid-2026, showed statistically significant improvements across endpoints and validated a potential second indication. Still, with negligible revenue and an EPS that remains negative, the stock's valuation is driven by future expectations rather than current fundamentals.

What Could Support a Move Toward the Target

Several verified factors could support a higher valuation. Pemvidutide's differentiation — particularly lean-mass preservation and liver-fat reduction relative to competing GLP-1 therapies — is a recurring theme in bullish research. Positive Phase 2 RECLAIM data in AUD expanded the potential addressable market beyond MASH, and Barclays described the readout as highlighting a meaningful opportunity. The company's cash position (roughly $326 million in recent filings) and management's stated runway through the MASH 52-week readout reduce near-term financing overhang, a point H.C. Wainwright cited as "a clear net positive." Insiders, including the CFO and directors, have also been purchasers of shares in 2026.

What Could Prevent the Target From Being Reached

The obstacles are substantial. Altimmune remains pre-commercial, with revenue in the tens of thousands of dollars against operating losses in the tens of millions annually. Advancing a Phase 3 AUD program may require additional capital that is not yet secured. Pemvidutide also faces gastrointestinal tolerability challenges and historically elevated discontinuation rates, which could constrain dosing or adherence. Competition from Novo Nordisk and Eli Lilly, both far larger and better capitalized, creates enrollment and commercialization headwinds. Finally, the extreme dispersion in analyst targets — from $10 to $28 — reflects genuine uncertainty about the probability of clinical and regulatory success.

Technical Levels and Market Structure

From a technical standpoint, ALT sits near its 52-week low of roughly $2.02, which functions as a key support level. A breakdown below this area would signal further downside risk. The 50-day and 200-day simple moving averages both sit near $2.99, meaning the stock trades well below its longer-term trend and would need to reclaim that zone before any sustained recovery could be considered. The $6.44 52-week high represents the nearest major overhead resistance level, followed by psychological price levels well above it. The stock's beta near 0.06 indicates it has moved largely on company-specific, clinical news rather than broad market direction. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge momentum shifts.

Time Horizon and What Investors Should Monitor

Analyst price targets for ALT generally reflect a roughly 12-month research horizon, though the wide dispersion in targets suggests analysts are effectively underwriting events that lie years out, such as the 2029 MASH readout. Nearer-term, investors should watch the company's earnings report (expected in November 2026), any updates on the Phase 3 PERFORMA trial enrollment and the AUD program, financing or partnership announcements, and further analyst target revisions. Regulatory milestones and competitive data from larger GLP-1 developers are also relevant to the long-term thesis.

My Take: Can ALT Reach $17?

Can Altimmune (ALT) stock reach $17? The question is not whether the arithmetic mean of analyst targets points there — it does — but whether the company can convert its clinical pipeline into demonstrable, de-risked value. A roughly 730% move from current levels is a very large ask that would require successful Phase 3 execution, broader indication validation, and sustained investor conviction against formidable competition. The bull case rests on pemvidutide's differentiation and an expanded AUD opportunity; the bear case rests on cash burn, tolerability, and execution risk. With targets ranging from $10 to $28, there is no consensus about magnitude, only broad agreement that the outcome hinges on clinical data. Investors should weigh these factors carefully and monitor upcoming earnings, pipeline updates, and financing developments rather than treating any single price target as a foregone conclusion.

Using AI Daily Buy/Sell Signals in Practice

In my research workflow, Tickeron's AI Daily Buy/Sell Signals provide a helpful layer for tracking momentum in volatile names like ALT. The tool applies artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical and market shifts. For clinical-stage biotechs driven by news flow, it helps flag potential changes in trend without relying solely on manual chart review. Traders looking to layer systematic signals onto fundamental work may find it a practical complement.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume